Wed, October 19, 2022
Tue, October 18, 2022
Mon, October 17, 2022
Sat, October 15, 2022
Fri, October 14, 2022
Thu, October 13, 2022

Joseph Schwartz Maintained (SRPT) at Buy with Increased Target to $145 on, Oct 17th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-145-on-oct-17th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Joseph Schwartz of SVB Leerink, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $126 to $145 on, Oct 17th, 2022.

Joseph has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 2 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022
  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $93 on, Wednesday, August 3rd, 2022


These are the ratings of the 4 analyists that currently disagree with Joseph


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $124 on, Thursday, August 18th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $182 on, Tuesday, August 9th, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $162 on, Friday, July 29th, 2022
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022

Publication Contributing Sources